Valuations on a day to day basis are meaningless to long term holders who are aware of the strategy employed by the company. Investment in growth, new products complimentary to that already existing, RD expenditure, expansion of staff to grab more of the market. MTX just another part of the strategy. News of its affect will be revealed in the half yearly report in Jan / Feb 2023. My investment policy when investing is disruptive medical technology, buy , hold hold hold.
Ann: FDA 510(k) clearance for NovoSorb MTX, page-45
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.75 |
Change
0.065(2.43%) |
Mkt cap ! $1.891B | |||
| Open | High | Low | Value | Volume |
| $2.69 | $2.75 | $2.66 | $1.703M | 627.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 28 | 24983 | $2.74 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.75 | 114995 | 25 |
View Market Depth
| Last trade - 11.58am 01/08/2024 (20 minute delay) ? |
| PNV (ASX) Chart |